Pacific Biosciences of California Inc (NASDAQ:PACB) price on current trading day, rose 2.46% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.25.
A look at the stock’s price movement, the close in the last trading session was $1.22, moving within a range at $1.21 and $1.3. The beta value (5-Year monthly) was 1.859. Turning to its 52-week performance, $4.10 and $1.16 were the 52-week high and 52-week low respectively. Overall, PACB moved -33.16% over the past month.
Pacific Biosciences of California Inc’s market cap currently stands at around $372.32 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-12.
Analysts have a consensus estimate of 33.72M for the company’s revenue for the quarter, with a low and high estimate of 31.29M and 35.13M respectively. The average forecast suggests down to a -13.11% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 161.59M, representing a 4.92% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PACB is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
11 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 4 analyst(s) rate the stock as a Hold, 6 recommend PACB as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PACB’s current price about -9.60% and -20.09% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 40.15, while 7-day volatility ratio is 7.21% and 9.64% in the 30-day chart. Further, Pacific Biosciences of California Inc (PACB) has a beta value of 2.02, and an average true range (ATR) of 0.13. Analysts have given the company’s stock an average 52-week price target of $3, forecast between a low of $2 and high of $4. Looking at the price targets, the low is -60.0% off current price level while to achieve the yearly target high, price needs to move -220.0%. Nonetheless, investors will most likely welcome a -140.0% jump to $3 which is the analysts’ median price.
If we refocus on Pacific Biosciences of California Inc (NASDAQ:PACB), historical trading data shows that trading volumes averaged 9.48 over the past 10 days and 11.24 million over the past 3 months. The company’s latest data on shares outstanding shows there are 273.86 million shares.
The 11.08% of Pacific Biosciences of California Inc’s shares are in the hands of company insiders while institutional holders own 84.41% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 61.98 million on 2025-02-28, giving us a short ratio of 4.47. The data shows that as of 2025-02-28 short interest in Pacific Biosciences of California Inc (PACB) stood at 2399.0 of shares outstanding, with shares short rising to 60.4 million registered in 2025-01-31. Current price change has pushed the stock -31.69% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PACB stock continues to rise going into the next quarter.
